[go: up one dir, main page]

NO963097L - Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4 - Google Patents

Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4

Info

Publication number
NO963097L
NO963097L NO963097A NO963097A NO963097L NO 963097 L NO963097 L NO 963097L NO 963097 A NO963097 A NO 963097A NO 963097 A NO963097 A NO 963097A NO 963097 L NO963097 L NO 963097L
Authority
NO
Norway
Prior art keywords
humanized antibodies
adhesion molecule
leukocyte adhesion
molecule vla
vla
Prior art date
Application number
NO963097A
Other languages
English (en)
Other versions
NO319867B1 (no
NO963097D0 (no
Inventor
Mary M Bendig
Olivier J Leger
Jose W Saldanha
Tarran S Jones
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Publication of NO963097D0 publication Critical patent/NO963097D0/no
Publication of NO963097L publication Critical patent/NO963097L/no
Publication of NO319867B1 publication Critical patent/NO319867B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19963097A 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff. NO319867B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (3)

Publication Number Publication Date
NO963097D0 NO963097D0 (no) 1996-07-24
NO963097L true NO963097L (no) 1996-09-24
NO319867B1 NO319867B1 (no) 2005-09-26

Family

ID=22684288

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19963097A NO319867B1 (no) 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff.
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO2017040C NO2017040I2 (no) 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO2017040C NO2017040I2 (no) 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Country Status (21)

Country Link
EP (2) EP0804237B8 (no)
JP (5) JP4115517B2 (no)
KR (1) KR100367948B1 (no)
CN (1) CN1211123C (no)
AT (1) ATE333895T1 (no)
AU (1) AU703152B2 (no)
CA (1) CA2182013C (no)
DE (2) DE69535133T2 (no)
DK (2) DK1759709T3 (no)
ES (2) ES2424292T3 (no)
FI (1) FI117509B (no)
FR (1) FR06C0024I2 (no)
HU (1) HU220799B1 (no)
LU (1) LU91271I2 (no)
MX (1) MX9602971A (no)
NL (1) NL300238I2 (no)
NO (3) NO319867B1 (no)
NZ (1) NZ279730A (no)
PL (1) PL181827B1 (no)
PT (1) PT804237E (no)
WO (1) WO1995019790A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DK1113810T3 (da) * 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
SK287328B6 (sk) * 1999-04-22 2010-07-07 Biogen Idec Ma Inc. Použitie kompozície obsahujúcej homológ protilátky, ktorý je antagonistom interakcie medzi integrínom nesúcim podjednotku alfa4 a ligandom pre integrín nesúci podjednotku alfa4
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2140881B1 (en) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200300509A (et) 2001-04-13 2004-08-16 Biogen, Inc. Antikehad VLA-1 vastu
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PT2336184E (pt) * 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
CA2587597A1 (en) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
DK2034830T3 (da) 2006-05-25 2014-10-27 Biogen Idec Inc Anti-vla-1-antistof til behandling af slagtilfælde
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
AR067011A1 (es) * 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
WO2009075388A1 (ja) 2007-12-13 2009-06-18 Tokuyama Corporation フォトクロミック硬化性組成物
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α４β７雜二聚體專一性拮抗抗體
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
MX340683B (es) 2010-04-16 2016-07-21 Biogen Ma Inc Anticuerpos anti-vla-4.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
PH12018502221B1 (en) 2011-05-02 2023-05-10 Millennium Pharm Inc FORMULATION FOR ANTI-a4ß7 ANTIBODY
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN110997714B (zh) * 2017-02-17 2024-05-03 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
US12043845B2 (en) 2017-06-08 2024-07-23 Polpharma Biologics S.A. Methods of cell culture
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
ATE151642T1 (de) * 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
AU688751B2 (en) * 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
FI962958A0 (fi) 1996-07-24
PT804237E (pt) 2006-10-31
PL181827B1 (pl) 2001-09-28
ATE333895T1 (de) 2006-08-15
NO2017040I1 (no) 2017-08-01
DK0804237T3 (da) 2006-10-16
NO2006008I2 (no) 2009-06-15
MX9602971A (es) 1998-01-31
JP5487382B2 (ja) 2014-05-07
EP1759709A1 (en) 2007-03-07
CA2182013A1 (en) 1995-07-27
CN1140413A (zh) 1997-01-15
EP1759709B1 (en) 2013-02-27
JPH09508272A (ja) 1997-08-26
KR970700513A (ko) 1997-02-12
JP2013165718A (ja) 2013-08-29
FI117509B (fi) 2006-11-15
JP2006045237A (ja) 2006-02-16
JP4115517B2 (ja) 2008-07-09
FI962958L (fi) 1996-09-24
KR100367948B1 (ko) 2003-07-12
NO319867B1 (no) 2005-09-26
NO2006008I1 (no) 2006-08-07
JP2009235078A (ja) 2009-10-15
CA2182013C (en) 2007-07-17
AU1696095A (en) 1995-08-08
HUT75129A (en) 1997-04-28
DE122006000043I1 (de) 2007-02-15
LU91271I2 (fr) 2006-10-02
NO963097D0 (no) 1996-07-24
EP0804237A1 (en) 1997-11-05
AU703152B2 (en) 1999-03-18
HU9602019D0 (en) 1996-09-30
NO2017040I2 (no) 2018-08-28
DE69535133D1 (de) 2006-09-07
EP0804237B1 (en) 2006-07-26
NZ279730A (en) 1998-04-27
PL315634A1 (en) 1996-11-25
ES2270425T3 (es) 2007-04-01
FR06C0024I1 (no) 2006-10-13
HU220799B1 (hu) 2002-05-28
WO1995019790A1 (en) 1995-07-27
FR06C0024I2 (fr) 2009-01-02
NL300238I1 (no) 2006-10-02
ES2424292T3 (es) 2013-09-30
EP0804237B8 (en) 2006-11-08
DK1759709T3 (da) 2013-06-10
EP0804237A4 (en) 2003-04-16
JP2013173738A (ja) 2013-09-05
NL300238I2 (nl) 2007-05-01
CN1211123C (zh) 2005-07-20
DE69535133T2 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
FI962958A0 (fi) Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan
NO961151D0 (no) Antistoffer mot CD40
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
DE59609954D1 (de) Katalytisch wirksame aktivatorkomplexe für persauerstoffverbindungen
DE3689734D1 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE69116921D1 (de) Verfahren zur Reinigung von monoklonalen Antikörpern
IL141158A0 (en) A humanized immunoglobulin which binds to human von willebrand factor
DE69502348D1 (de) Verfahren für die Reaktion von Perfluoralkyljodiden mit olefinischen Verbindungen
NO179328C (no) Antistoffer mot retinoblastom-genprodukt, anvedelse derav samt murint hybridom
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TYSABRI - NATALIZUMAB; NAT. REG. NO/DATE: EU106346001NO 20060713

Spc suppl protection certif: 2006008

Filing date: 20060807

Extension date: 20200125

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: TYSABRI - NATALIZUMAB; NAT. REG. NO/DATE: EU106346001NO 20060713

Spc suppl protection certif: 2006008

Filing date: 20060807

Extension date: 20200125

MK1K Patent expired
SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: NATALIZUMAB, ANTI ALFA-4 INTEGRIN HUMANISERT MONOKLONALT ANTISTOFF; NAT. REG. NO/DATE: EU/1/06/346/001 20060627; FIRST REG. NO/DATE: EU , EU/1/06/346/001 20060627

Spc suppl protection certif: 2017040

Filing date: 20170801

SPCH Extension of a supplementary protection certificate (spc) granted

Free format text: PRODUCT NAME: NATALIZUMAB, ANTI ALFA-4 INTEGRIN HUMANISERT MONOKLONALT ANTISTOFF; NAT. REG. NO/DATE: EU/1/06/346/001 20060627; FIRST REG. NO/DATE: EU , EU/1/06/346/001 20060627

Spc suppl protection certif: 2017040

Filing date: 20170801

SPCX Expiry of an spc

Spc suppl protection certif: 2006008